Journal ArticleDOI
A stunning day in hypertension research – Results of ONTARGET, ACCOMPLISH and HYVET
Reads0
Chats0
TLDR
The main outcome results of The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET), Avoiding Cardiovascular Events through COMbination Therapy in Patients LIving with Systolic Hypertension (ACCOMPLISH) and The HYpertension in the Very Elderly Trial (HYVET) were presented by Salim Yusef, Kenneth Jamerson and Nigel Beckett.Abstract:
As exciting as it can be, with plenary session jammed with interested delegates in numbers of many thousands, three new breathtaking double‐blinded randomized clinical trials were released within 4...read more
Citations
More filters
Journal ArticleDOI
Chlorthalidone Decreases Platelet Aggregation and Vascular Permeability and Promotes Angiogenesis
TL;DR: It can be suggested from the findings that thiazides and thiazide-like diuretics vary in their pleiotropic effects on platelets and in the vasculature, and these differences could explain the contrasting ability of these drugs to reduce cardiovascular morbidity despite comparable reduction in blood pressure.
Journal ArticleDOI
Combining RAAS and calcium channel blockade: ACCOMPLISH in perspective
TL;DR: Data from trials comparing ARB and ACEI therapies, and findings from studies of ARB/CCB combination therapy that support the use and further study of combination therapy with RAAS inhibitors and CCBs are reviewed.
Journal ArticleDOI
Achieving better blood pressure control.
TL;DR: In the present issue of Blood Pressure, Ruilope and co-workers argue for wider use of fixeddose antihypertensive combinations based on both individual patient benefits and, importantly, also on greater public health and societal value.
Journal ArticleDOI
More is Less? Optimal Combination Therapy for Adequate Blood Pressure Lowering in Hypertension
TL;DR: Data from multiple clinical studies in a range of patient populations indicate that ACEI and ARB provide similar cardiovascular benefits, and it appears reasonable to explore the possibility that the beneficial results of ACCOMPLISH extend to other RAAS inhibitor/CCB combinations.
Patent
Treatment for Oxidative Stress and/or Hypertension
TL;DR: In this article, a mixture of tempol and an angiotensin receptor blocker (ARB) was used to treat oxidative stress and/or hypertension, and the use of said mixture to treat hypertension was described.
References
More filters
Journal ArticleDOI
Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events
Koon K. Teo,Janice Pogue,Leanne Dyal,Ingrid Copland,Helmut Schumacher,Gilles R. Dagenais,Craig S. Anderson +6 more
TL;DR: Telmisartan was equivalent to ramipril in patients with vascular disease or high-risk diabetes and was associated with less angioedema and a increased risk of hypotensive symptoms.
Journal ArticleDOI
A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.
Jay N. Cohn,Gianni Tognoni +1 more
TL;DR: Valsartan significantly reduces the combined end point of mortality and morbidity and improves clinical signs and symptoms in patients with heart failure, when added to prescribed therapy, and raises concern about the potential safety of this specific combination.
Journal ArticleDOI
Treatment of Hypertension in Patients 80 Years of Age or Older
Nigel Beckett,Ruth Peters,Astrid E. Fletcher,Jan A. Staessen,Lisheng Liu,D Dumitrascu,Vassil Stoyanovsky,Riitta Antikainen,Yuri Nikitin,Craig S. Anderson,Alli Belhani,Françoise Forette,Chakravarthi Rajkumar,Lutgarde Thijs,Winston Banya,Christopher J. Bulpitt +15 more
TL;DR: The results provide evidence that antihypertensive treatment with indapamide (sustained release), with or without perindopril, in persons 80 years of age or older is beneficial.
Journal ArticleDOI
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial
Christopher B. Granger,John J.V. McMurray,Salim Yusuf,Peter Held,Eric L. Michelson,Bertil Olofsson,Jan Östergren,Marc A. Pfeffer,Karl Swedberg +8 more
TL;DR: The addition of candesartan to ACE inhibitor and other treatment leads to a further clinically important reduction in relevant cardiovascular events in patients with CHF and reduced left-ventricular ejection fraction.
Journal Article
Evidence-based cardiology Ramipryl i telmisartan podobnie skutecznie zapobiegają incydentom wieńcowym – wyniki badania ONTARGET. Commentary to the article: ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-59.
Related Papers (5)
Benazepril plus amlodipine or hydrochlorothiazide for hypertension.
Barry R. Davis,Paul K. Whelton +1 more
Combined Antihypertensive Therapy and Sexual Dysfunction: Terra Incognita
Effect of oxygen cocktail on the cardiohemodynamics in complex treatment of hypertension
N S Zanozdra,V R Nazarenko +1 more